|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: NEXIUM
Summary for Tradename: NEXIUM
|
|
Latest news for NEXIUMTo Your Good Health: Using Tylenol to treat rheumatoid arthritis24 May 2013, 11:42 am The 5 Highest-Paying Dividend Stocks in Big Pharma22 May 2013, 11:30 am Santarus Is a Real Gas!21 May 2013, 12:20 pm Roundup: Giant Eagle sues drug makers over generics; Fed says mistakes made in mortgage settlement; more8 May 2013, 10:01 pm Giant Eagle sues drug makers, claims they delayed generic drug8 May 2013, 7:16 pm VIVUS Announces Richard Fante, Former President U.S. and CEO North America, AstraZeneca, to Serve as Senior Advisor7 May 2013, 7:00 am Drugs.com Releases Q1 Sales for Top 100 U.S. Drugs: Rough U.S Flu Season Boosts Numbers for Tamiflu6 May 2013, 8:59 am Watch: Fast Food Value Meals4 May 2013, 11:28 pm AstraZeneca Earnings Tumble Y/Y26 April 2013, 12:20 pm Courtesy of Yahoo News | ||||||||||||
Clinical Trials for: NEXIUMNexium Study To Suppress Nausea During Chemotherapy Status: Terminated Condition: Nausea The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Status: Completed Condition: Type 2 Diabetes Viokase 16, Viokase16 Plus Nexium and Nexium Alone Status: Terminated Condition: Chronic Pancreatitis A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050 AM1)(CL2010-12) Status: Completed Condition: Heartburn Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers Status: Completed Condition: Healthy A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels Status: Completed Condition: Arthritis Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Status: Completed Condition: Gastroesophageal Reflux Disease Prevention of Gastric Ulcers Status: Completed Condition: NSAID Associated Gastric Ulcers Optimal Dosing of Omeprazole in Neonates Status: Completed Condition: Gastroesophageal Reflux Disease (GERD) Ulcer Prevention II Status: Completed Condition: NSAID Associated Gastric Ulcers Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca | NEXIUM | esomeprazole magnesium | CAPSULE, DELAYED REL PELLETS; ORAL | 021153 | Feb 20, 2001 | RX | No | 5,690,960*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Astrazeneca | NEXIUM | esomeprazole magnesium | CAPSULE, DELAYED REL PELLETS; ORAL | 021153 | Feb 20, 2001 | RX | No | 5,714,504*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Astrazeneca | NEXIUM | esomeprazole magnesium | CAPSULE, DELAYED REL PELLETS; ORAL | 021153 | Feb 20, 2001 | RX | No | 5,877,192*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Astrazeneca | NEXIUM | esomeprazole magnesium | CAPSULE, DELAYED REL PELLETS; ORAL | 021153 | Feb 20, 2001 | RX | No | 5,900,424*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: NEXIUM
| Drugname | Dosage | Strength | RLD | Submissiondate |
| esomeprazole sodium | For Injection | 20 mg/vial and 40 mg/vial | Nexium IV | 11/23/2009 |
| esomeprazole magnesium | Delayed-release | 20 mg and 40 mg | Nexium | 8/5/2005 |
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc